8-K: Vivos Therapeutics Receives Nasdaq Deficiency Notice

Vivos Therapeutics has been notified by Nasdaq that it fails to meet the minimum stockholders' equity requirement for continued listing.

Summary

• Vivos Therapeutics received a notice from Nasdaq on April 17, 2026, stating it does not meet the minimum stockholders' equity requirement of $2.5 million.
• As of December 31, 2025, the company reported a negative stockholders' equity of approximately $1.55 million.
• The company has until June 1, 2026, to submit a compliance plan to Nasdaq.
• If the plan is accepted, the company may receive an extension until October 14, 2026, to regain compliance.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative development due to the threat of delisting and the underlying financial instability indicated by negative stockholders' equity.

Positives

• The company raised $6.8 million in gross proceeds through two equity financing transactions during Q1 2026.
• The notice has no immediate impact on the current listing of the company's common stock on Nasdaq.

Negatives

• The company failed to meet the Nasdaq Listing Rule 5550(b)(1) requirement for stockholders' equity.
• Reported negative stockholders' equity of $1.55 million as of year-end 2025.
• There is no guarantee that the proposed compliance plan will be accepted by Nasdaq.

Risks

• Potential delisting from the Nasdaq Stock Market if compliance is not regained.
• Material adverse effect on operations and reputation if delisting occurs.
• Inability to raise sufficient capital or improve operational results to meet the $2.5 million equity threshold.

Future Outlook

The company intends to submit a plan to regain compliance by June 1, 2026, and will continue efforts to bolster stockholders' equity through operational improvements or further financing.

Management Comments

• The company acknowledges the deficiency and is actively working on a plan to regain compliance with Nasdaq listing standards.

Industry Context

StockSavvy.ai notes that small-cap medical device companies frequently face Nasdaq compliance challenges during periods of high cash burn and R&D investment, often necessitating dilutive equity raises to maintain listing status.

Comparison to Industry Standards

• The company's struggle with equity thresholds is common among micro-cap healthcare firms.
• Reliance on private placements and warrant exercises is a standard, albeit dilutive, mechanism for capital-constrained firms to address balance sheet deficiencies.

Stakeholder Impact

• Shareholders face potential volatility and liquidity risks associated with a possible delisting.
• Creditors may reassess credit terms given the company's equity deficiency.

Next Steps

• Submit a compliance plan to Nasdaq by June 1, 2026.
• Continue efforts to improve stockholders' equity through operational results or further capital raises.

Key Dates

Recommendation

The combination of negative stockholders' equity and the threat of Nasdaq delisting presents significant execution risk, making the stock unattractive until a clear path to sustained compliance and profitability is established.

Keywords

Vivos Therapeutics, Nasdaq, delisting, stockholders equity, compliance, VVOS, equity financing